Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
Terminated · Phase 2 · NCT04394624
Conditions: Non-small Cell Lung Cancer Metastatic
At a glance
- Research payments reported, 2025
- $7,643
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 31
About the trial
- Sponsor
- Sanofi
- Tested
- SAR408701 (drug), ramucirumab (drug), pembrolizumab (drug)
- Dates
- Started 2020-08-31; completion 2024-10-24
- Results posted
- Yes
Primary Objectives: Doublet Cohort Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population. Triplet cohort To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab and pembrolizumab in the NSQ NSCLC population. Secondary Objectives: Doublet Cohort To assess the safety and tolerability of tusamitamab ravtansine in combination with ramucirumab. To assess the durability of the response to…
From ClinicalTrials.gov, last updated 2025-06-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $7,643 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Baylor Research Institute Bri $7,643
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.